Post-esophagectomy gastric conduit cancers: treatment experiences and literature review

Dis Esophagus. 2014 Feb-Mar;27(2):141-5. doi: 10.1111/dote.12070. Epub 2013 Apr 2.

Abstract

Esophagectomy remains the mainstay of treatment for esophageal cancer. The stomach is the commonest organ used to restore intestinal continuity after esophagectomy. Metachronous gastric cancer in the gastric conduit after esophagectomy is rare; the etiology remains unclear. Possible risk factors include Helicobacter pylori infection, biliary or pancreatic reflux and prior radiotherapy. Prognosis of these patients remains poor. Treatment of this particular entity poses unique challenges to the surgeon and oncologist. Early diagnosis by endoscopy may allow endoscopic excision such as endoscopic mucosal resection or endoscopic submucosal dissection. In more advanced cancers, surgery is difficult, reconstruction is complicated, and further radiation may not be feasible because of previous neoadjuvant therapy. In this report, four patients who developed gastric conduit cancers are presented. They were treated with either surgery alone or combined with chemoradiotherapy. All four patients were still alive after at least 21 months, with three patients currently still alive (21-48 months). The literature is also reviewed, in particular addressing the incidence, possible underlying causes, prognosis and options of treatment for this specific clinical scenario.

Publication types

  • Case Reports
  • Review

MeSH terms

  • Adenocarcinoma / surgery*
  • Aged
  • Carcinoma, Signet Ring Cell / surgery*
  • Carcinoma, Squamous Cell / surgery*
  • Esophageal Neoplasms / surgery*
  • Esophagectomy
  • Female
  • Gastrectomy
  • Humans
  • Male
  • Middle Aged
  • Neoplasms, Second Primary / surgery*
  • Stomach Neoplasms / surgery*